Physician profile
Michael S Gilinsky
NPI 1154374270
$1,115.37
in general payments reported to CMS, 2019-2025
17 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $94.53 · 2021: $195 · 2023: $314 · 2024: $72.37 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $231.40 | 2023 | Proclaim |
| Astrazeneca Pharmaceuticals Lp | $196.76 | 2019-2025 | Airsupra |
| Pfizer INC. | $170.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.85 | 2019-2025 | Xifaxan |
| Allergan, INC. | $65.64 | 2019-2020 | |
| Saluda Medical Americas, INC. | $42.21 | 2025 | Evoke |
| Redhill Biopharma INC. | $30.71 | 2020 | |
| Sumitomo Pharma America, INC. | $26.81 | 2023 | Gemtesa |
| Exact Sciences Corporation | $25.42 | 2025 | The Cologuard Plus Collection Kit |
| Organogenesis INC. | $25.02 | 2025 | Via Matrix |
| Glaxosmithkline, LLC. | $24.39 | 2023 | Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $23.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.86 | 2020 | |
| Urovant Sciences INC | $22.07 | 2021 | |
| Biogen, INC. | $21.41 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.83 | 2021 | |
| Solventum Corporation | $18.43 | 2025 | Adaptic, 3m Cavilon, Promogran |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gilinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.